$NKTR
NEKTAR THERAPEUTICS

2013 Q2 Form 10-Q Financial Statement

#000119312513211264 Filed on May 09, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $33.86M $23.00M $17.95M
YoY Change 42.97% 28.16% 58.85%
Cost Of Revenue $5.011M $11.66M $8.707M
YoY Change -30.43% 33.93% 166.84%
Gross Profit $28.85M $11.34M $9.242M
YoY Change 75.06% 22.73% 15.01%
Gross Profit Margin 85.2% 49.31% 51.49%
Selling, General & Admin $9.200M $10.80M $10.40M
YoY Change -10.68% 3.85% -11.11%
% of Gross Profit 31.89% 95.21% 112.53%
Research & Development $52.23M $45.62M $35.09M
YoY Change 57.31% 30.02% 16.27%
% of Gross Profit 181.03% 402.17% 379.63%
Depreciation & Amortization $3.700M $3.600M $3.500M
YoY Change 5.71% 2.86% -10.26%
% of Gross Profit 12.82% 31.74% 37.87%
Operating Expenses $52.23M $45.62M $35.09M
YoY Change 57.31% 30.02% 16.27%
Operating Profit -$32.61M -$45.11M -$37.93M
YoY Change 20.81% 18.91% 12.0%
Interest Expense $4.656M $4.645M $2.548M
YoY Change 81.73% 82.3% -227.4%
% of Operating Profit
Other Income/Expense, Net -$9.938M -$9.747M -$3.041M
YoY Change 37.95% 220.52%
Pretax Income -$42.54M -$54.85M -$40.97M
YoY Change 24.42% 33.87% 14.13%
Income Tax $205.0K $212.0K $124.0K
% Of Pretax Income
Net Earnings -$42.75M -$55.06M -$41.10M
YoY Change 24.68% 33.98% 14.05%
Net Earnings / Revenue -126.24% -239.36% -228.97%
Basic Earnings Per Share -$0.37 -$0.48
Diluted Earnings Per Share -$0.37 -$0.48 -$359.0K
COMMON SHARES
Basic Shares Outstanding 115.5M shares 115.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $201.9M $236.2M $382.1M
YoY Change -53.36% -38.18% -26.32%
Cash & Equivalents $41.43M $28.53M $148.5M
Short-Term Investments $160.5M $207.7M $233.6M
Other Short-Term Assets $6.018M $8.813M $13.60M
YoY Change -35.29% -35.2% 97.1%
Inventory $20.48M $18.38M $14.10M
Prepaid Expenses
Receivables $6.041M $3.647M $10.80M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $234.4M $267.0M $420.7M
YoY Change -49.94% -36.53% -22.01%
LONG-TERM ASSETS
Property, Plant & Equipment $67.85M $70.11M $75.60M
YoY Change -7.94% -7.26% -13.7%
Goodwill $76.50M $76.50M
YoY Change
Intangibles
YoY Change
Long-Term Investments $116.7M
YoY Change
Other Assets $9.036M $9.252M $5.300M
YoY Change 58.53% 74.57% 430.0%
Total Long-Term Assets $178.4M $180.9M $274.1M
YoY Change -10.85% -34.01% 66.02%
TOTAL ASSETS
Total Short-Term Assets $234.4M $267.0M $420.7M
Total Long-Term Assets $178.4M $180.9M $274.1M
Total Assets $412.8M $447.9M $694.8M
YoY Change -38.24% -35.54% -1.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.572M $4.218M $1.800M
YoY Change 79.74% 134.33% -48.57%
Accrued Expenses $11.36M $6.946M $28.70M
YoY Change -63.13% -75.8% -6.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $215.0M
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $90.28M $83.22M $270.8M
YoY Change -67.4% -69.27% 359.76%
LONG-TERM LIABILITIES
Long-Term Debt $134.9M $135.8M $139.7M
YoY Change -4.26% -2.79% -39.63%
Other Long-Term Liabilities $8.623M $9.015M $121.9M
YoY Change -92.72% -92.6% -8.35%
Total Long-Term Liabilities $8.623M $9.015M $261.6M
YoY Change -96.67% -96.55% -28.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $90.28M $83.22M $270.8M
Total Long-Term Liabilities $8.623M $9.015M $261.6M
Total Liabilities $453.4M $450.5M $532.3M
YoY Change -15.45% -15.36% 25.78%
SHAREHOLDERS EQUITY
Retained Earnings -$1.668B -$1.625B
YoY Change
Common Stock $1.629B $1.623B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$40.55M -$2.620M $162.5M
YoY Change
Total Liabilities & Shareholders Equity $412.8M $447.9M $694.8M
YoY Change -38.24% -35.54% -1.38%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$42.75M -$55.06M -$41.10M
YoY Change 24.68% 33.98% 14.05%
Depreciation, Depletion And Amortization $3.700M $3.600M $3.500M
YoY Change 5.71% 2.86% -10.26%
Cash From Operating Activities -$34.30M -$38.11M -$34.62M
YoY Change 66.5% 10.09% 132.34%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K $316.0K $1.516M
YoY Change -70.59% -79.16% -139.89%
Acquisitions
YoY Change
Other Investing Activities $47.10M $44.00M $49.90M
YoY Change 395.79% -11.82% -125.19%
Cash From Investing Activities $46.60M $43.69M $48.43M
YoY Change 497.44% -9.79% -123.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 700.0K -2.474M 119.5M
YoY Change 133.33% -102.07% -46.05%
NET CHANGE
Cash From Operating Activities -34.30M -38.11M -34.62M
Cash From Investing Activities 46.60M 43.69M 48.43M
Cash From Financing Activities 700.0K -2.474M 119.5M
Net Change In Cash 13.00M 3.101M 133.3M
YoY Change -204.0% -97.67% 2736.36%
FREE CASH FLOW
Cash From Operating Activities -$34.30M -$38.11M -$34.62M
Capital Expenditures -$500.0K $316.0K $1.516M
Free Cash Flow -$33.80M -$38.43M -$36.13M
YoY Change 78.84% 6.35% 225.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
115522958 shares
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148485000
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2013Q1 us-gaap Other Assets Current
OtherAssetsCurrent
8813000
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8952000
CY2013Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-395000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
83221000
CY2013Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
9779000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
23239000
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1625443000
CY2013Q1 us-gaap Assets
Assets
447901000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28531000
CY2013Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
8126000
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3647000
CY2013Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
207664000
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
447901000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115461000 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
11000
CY2013Q1 us-gaap Inventory Net
InventoryNet
18381000
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9252000
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q1 us-gaap Goodwill
Goodwill
76501000
CY2013Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12667000
CY2013Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.12 pure
CY2013Q1 us-gaap Liabilities
Liabilities
450521000
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6946000
CY2013Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
476000
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70112000
CY2013Q1 us-gaap Other Deferred Credits Noncurrent
OtherDeferredCreditsNoncurrent
2185000
CY2013Q1 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
25000000
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
115461000 shares
CY2013Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3167000
CY2013Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
97918000
CY2013Q1 us-gaap Assets Current
AssetsCurrent
267036000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
213313000
CY2013Q1 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
148900000
CY2013Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1623207000
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
-2620000
CY2013Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
10766000
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9015000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4218000
CY2013Q1 nktr Debt Instrument Maturity Month And Year
DebtInstrumentMaturityMonthAndYear
2017-07
CY2013Q1 nktr Cash And Restricted Cash
CashAndRestrictedCash
26200000
CY2013Q1 nktr Estimated Fair Value Of Cash Cash Equivalents And Available For Sale Investments
EstimatedFairValueOfCashCashEquivalentsAndAvailableForSaleInvestments
261195000
CY2013Q1 nktr License And Collaboration Agreements Potential Payments For Development Milestones
LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones
161100000
CY2013Q1 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
24032000
CY2013Q1 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2013Q1 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
122416000
CY2013Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
261195000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15312000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13363000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8773000
CY2012Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-357000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78537000
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
6661000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21896000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1570380000
CY2012Q4 us-gaap Assets
Assets
497790000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25437000
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
7489000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5805000
CY2012Q4 us-gaap Inventory Net
InventoryNet
18269000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9443000
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
251757000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
497790000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115259000 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Goodwill
Goodwill
76501000
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12414000
CY2012Q4 us-gaap Liabilities
Liabilities
450772000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8008000
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4119000
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72215000
CY2012Q4 us-gaap Other Deferred Credits Noncurrent
OtherDeferredCreditsNoncurrent
2404000
CY2012Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
25000000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
115259000 shares
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7083000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
96551000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
314631000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
252760000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1617744000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
47018000
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
11607000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8407000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2863000
CY2012Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
26947000
CY2012Q4 nktr Estimated Fair Value Of Cash Cash Equivalents And Available For Sale Investments
EstimatedFairValueOfCashCashEquivalentsAndAvailableForSaleInvestments
302194000
CY2012Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
17500000
CY2012Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2012Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
128266000
CY2012Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
302194000
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000906709
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 dei Trading Symbol
TradingSymbol
NKTR
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
427000
CY2013Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1218000
CY2013Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3830000
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3844000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43686000
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
314000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45618000
CY2013Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.32 pure
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2710000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2158000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-54851000
CY2013Q1 us-gaap Interest Paid
InterestPaid
8250000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4245000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3628000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3094000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-45404000
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-139000
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
112000
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
11661000
CY2013Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
692000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-55063000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9447000
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
68408000
CY2013Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
179000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11129000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2474000
CY2013Q1 us-gaap Royalty Revenue
RoyaltyRevenue
325000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55101000
CY2013Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
100338000
CY2013Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-3916000
CY2013Q1 us-gaap Revenues
Revenues
23004000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
212000
CY2013Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-7000
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
316000
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11810000
CY2013Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
56336000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4245000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15343000 shares
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. On an ongoing basis, we evaluate our estimates, including those related to deferred revenue recognition periods, inventories, the impairment of investments, the impairment of goodwill and long-lived assets, contingencies, accrued clinical trial expenses, estimated interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</font></p> </div>
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1130000
CY2013Q1 us-gaap Interest Expense
InterestExpense
4645000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1355000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38111000
CY2013Q1 nktr Number Of Business Segments
NumberOfBusinessSegments
1 Segment
CY2013Q1 nktr Proceeds From Issuance Of Senior Notes
ProceedsFromIssuanceOfSeniorNotes
125000000
CY2013Q1 nktr Noncash Interest Expense
NoncashInterestExpense
5543000
CY2013Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
4393000
CY2013Q1 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
6476000
CY2013Q1 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
6532000
CY2013Q1 nktr Weighted Average Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Share
WeightedAverageSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerShare
115309000 shares
CY2013Q1 nktr Debt Instrument Maximum Maturity Period
DebtInstrumentMaximumMaturityPeriod
Two years or less
CY2013Q1 nktr Debt Instrument Weighted Average Maturity Period One
DebtInstrumentWeightedAverageMaturityPeriodOne
One year or less
CY2013Q1 nktr Payment For Transaction Costs
PaymentForTransactionCosts
4400000
CY2013Q1 nktr Repayment Of Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
-3000000
CY2013Q1 nktr Estimated Annual Interest Rate
EstimatedAnnualInterestRate
0.17 pure
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
660000
CY2012Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
479000
CY2012Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
556000
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4305000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48425000
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
632000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35085000
CY2012Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.32 pure
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3226000
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5865000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-40973000
CY2012Q1 us-gaap Interest Paid
InterestPaid
4199000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4234000
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3510000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
133173000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37932000
CY2012Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-295000
CY2012Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1452000
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8707000
CY2012Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
566000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-41097000
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3041000
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
55881000
CY2012Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4620000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10414000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119502000
CY2012Q1 us-gaap Royalty Revenue
RoyaltyRevenue
3177000
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40037000
CY2012Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
151964000
CY2012Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-1747000
CY2012Q1 us-gaap Revenues
Revenues
17949000
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
124000
CY2012Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-136000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1516000
CY2012Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1675000
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6945000
CY2012Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
102023000
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4234000
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23885000 shares
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1094000
CY2012Q1 us-gaap Interest Expense
InterestExpense
2548000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1290000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34618000
CY2012Q1 nktr Noncash Interest Expense
NoncashInterestExpense
1785000
CY2012Q1 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
7827000
CY2012Q1 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
773000
CY2012Q1 nktr Weighted Average Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Share
WeightedAverageSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerShare
114531000 shares
CY2012Q1 nktr Repayment Of Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
119589000

Files In Submission

Name View Source Status
0001193125-13-211264-index-headers.html Edgar Link pending
0001193125-13-211264-index.html Edgar Link pending
0001193125-13-211264.txt Edgar Link pending
0001193125-13-211264-xbrl.zip Edgar Link pending
d502940d10q.htm Edgar Link pending
d502940dex311.htm Edgar Link pending
d502940dex312.htm Edgar Link pending
d502940dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
nktr-20130331.xml Edgar Link completed
nktr-20130331.xsd Edgar Link pending
nktr-20130331_cal.xml Edgar Link unprocessable
nktr-20130331_def.xml Edgar Link unprocessable
nktr-20130331_lab.xml Edgar Link unprocessable
nktr-20130331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending